EPO

EQS-News: Heidelberg Pharma announces financial figures and reports on successful business performance in 2023

Retrieved on: 
Wednesday, April 10, 2024
Malignancy, Spanish mythology, State university system, Patient, Sale, Renal cell carcinoma, Clinical trial, Neoplasm, Therapy, Depreciation, HPHA, USD, Marketing, GLP, Health, Research, ATACS, EPO, Immune system, ADC, BLA, ATAC, Food, Biologics license application, Disease, Magenta, Multiple myeloma, AACR, GCC, Annual report, FDA, Diagnosis, EUR, Supervisory board, Accounting, PET, EDT, Spacecraft, Amanitin, European Patent Convention, Patent, Eli Lilly and Company, Binghamton University, Pharmaceutical industry

Minority interest in Emergence sold: In summer 2023, Heidelberg Pharma sold its minority interest in Emergence Therapeutics AG, Duisburg, Germany, (Emergence).

Key Points: 
  • Minority interest in Emergence sold: In summer 2023, Heidelberg Pharma sold its minority interest in Emergence Therapeutics AG, Duisburg, Germany, (Emergence).
  • As a result, Heidelberg Pharma lost sales revenue in the low single-digit millions for the 2023 financial year.
  • In April 2023, Heidelberg Pharma signed a termination agreement with Magenta under which all licensed ATAC rights and some Magenta patents were assumed by Heidelberg Pharma.
  • The Heidelberg Pharma Group includes two entities, Heidelberg Pharma AG and Heidelberg Pharma Research GmbH.

Completion of PIC/S Participating Authorities' Audits of Kexing Biopharm's Licensed Product Infliximab for Injection

Retrieved on: 
Tuesday, April 2, 2024
Certification, Brazilian Health Regulatory Agency, News, EPO, ANVISA, GMP, PIC/S, Infliximab, Food

New York, New York--(Newsfile Corp. - April 2, 2024) - The product infliximab for injection, licensed by Kexing Biopharm, has recently experienced a wave of encouraging news regarding its international commercialization.

Key Points: 
  • New York, New York--(Newsfile Corp. - April 2, 2024) - The product infliximab for injection, licensed by Kexing Biopharm, has recently experienced a wave of encouraging news regarding its international commercialization.
  • In addition, this month, the product has undergone a site GMP audit by another PIC/S Participating Authority, the Indonesian Food and Drug Authority (BPOM).
  • The company's proprietary product, human erythropoietin (EPO), has been present in Indonesia since 2005, gaining popularity and increasing market share.
  • In terms of infliximab, progress has been remarkable in the overseas factory inspection since the third quarter of 2023.

Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe

Retrieved on: 
Wednesday, April 3, 2024
Growth, Risk, Patient, EPO, European Patent Convention, Patent, Family, Professional corporation, SPCS, Triglyceride, Pharmaceutical industry

In addition, the Company recently achieved success defending a separate European VAZKEPA patent from third-party opposition within the EPO.

Key Points: 
  • In addition, the Company recently achieved success defending a separate European VAZKEPA patent from third-party opposition within the EPO.
  • Additional independent patent applications from this family remain pending, which when granted, will further reinforce VAZKEPA’s exclusivity in Europe until April 2039.
  • Additionally, in November 2023, Amarin successfully defended a separate patent containing claims covering VAZKEPA in Europe from third-party opposition.
  • At the conclusion of that opposition, the EPO found all claims for Amarin’s 2033 VAZKEPA patent to be valid.

Leading in health technology innovation: Philips one of the top patent applicants at European Patent Office

Retrieved on: 
Tuesday, March 19, 2024
Health, Informatics, PHG, Research, Software, AI, EPO, European Patent Convention, Patent, Intellectual property, Medtech, AEX, Medical device

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that it is one of the leading patent applicants at the European Patent Office (EPO).

Key Points: 
  • Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that it is one of the leading patent applicants at the European Patent Office (EPO).
  • Building on more than 130 years of innovation, Philips’ extensive global R&D programs and collaborations position the company at the forefront of health technology innovation.
  • With 607 MedTech patent applications in 2023, Philips is the second largest applicant in EPO's Patent Index 2023 in the field of medical technology.
  • In total, Philips contributed 1,299 patent applications across various domains, solidifying its standing among the top 10 patent filers overall.

BioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine

Retrieved on: 
Friday, March 15, 2024
The Orange Book, Agitation, Patent, Intelligence, Patient, Tablet, Heel, EPO, Orange Book, Therapy, European Patent Convention, Dexmedetomidine, FDA, Dementia, Pharmaceutical industry

The 486 patent covers the use of dexmedetomidine administered sublingually to treat agitation in individuals with dementia.

Key Points: 
  • The 486 patent covers the use of dexmedetomidine administered sublingually to treat agitation in individuals with dementia.
  • The patent encompasses a broad range of dosage forms, including films such as BXCL501 (sublingual dexmedetomidine), wafers, and tablets, at dexmedetomidine doses ranging from 3 mcg to 100 mcg.
  • 17/496,470 with claims pertaining to methods of treating agitation in patients with Alzheimer’s disease using the oromucosal administration of 60 mcg of dexmedetomidine in a water-soluble dosage form.
  • The patent, when issued, is expected to have an expiration date of July 17, 2040, subject to patent term adjustment, patent term extension, and terminal disclaimers.

Linnaeus Therapeutics Announces Issuance of Composition of Matter Patent for LNS8801 by the European Patent Office

Retrieved on: 
Tuesday, April 2, 2024
Salt, Progression-free survival, Patient, EPO, MD, Pembrolizumab, Human, Therapy, European Patent Convention, Safety, Pharmacokinetics, Randomized controlled trial, Patent, EP, Animal, SRR, Pharmaceutical industry

HADDONFIELD N.J., April 2, 2024 /PRNewswire/ -- Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of novel small molecule oncology therapeutics, today announced that on March 6, 2024, the European Patent Office (EPO) issued EP patent 3,823,617 ('617 patent) covering the pharmaceutical composition of matter for the company's lead compound, LNS8801.

Key Points: 
  • European Patent 3,823,617 Issued on March 6, 2024
    HADDONFIELD N.J., April 2, 2024 /PRNewswire/ -- Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of novel small molecule oncology therapeutics, today announced that on March 6, 2024, the European Patent Office (EPO) issued EP patent 3,823,617 ('617 patent) covering the pharmaceutical composition of matter for the company's lead compound, LNS8801.
  • "We are extremely pleased that the EPO has issued this composition of matter patent," commented Patrick Mooney, MD, CEO of Linnaeus.
  • As we continue to collect very promising data from our clinical trials with LNS8001, we will continue to prosecute the claims in this patent worldwide."
  • The study will enroll 135 patients who will be selected based on a predictive biomarker and then randomized to receive LNS8801 alone, LNS8801 and pembrolizumab, or physician's choice therapy.

Innovation in Healthcare and Digital Technologies Boosts European Patent Applications by U.S. Companies

Retrieved on: 
Tuesday, March 19, 2024
Boston Scientific, Growth, Biotechnology, Unitary, Unitary patent, Environment, EPO, Medtronic, Unified Patent Court, Samsung, Johnson & Johnson, European Patent Convention, Invention, Patent, Ericsson, South Korea, Multimedia, SME

MUNICH, March 19, 2024 /PRNewswire/ -- U.S. companies filed 48 155 patent applications at the European Patent Office last year, an increase of 0.4% compared to 2022, according to the EPO's Patent Index 2023 .

Key Points: 
  • MUNICH, March 19, 2024 /PRNewswire/ -- U.S. companies filed 48 155 patent applications at the European Patent Office last year, an increase of 0.4% compared to 2022, according to the EPO's Patent Index 2023 .
  • The U.S. thus accounted for 24.2% of the total patent applications received by the EPO in 2023.
  • The U.S. consistently ranks as the top filing country at the EPO, and the number of patent applications has increased by +31.3% since 2014.
  • The U.S. growth was driven by increased patent applications in healthcare and digital technologies, making up the five leading U.S technology fields with the most patent applications in Europe: medical technology (6 098 patent applications), computer technology (5 111), digital communication (5 008), pharmaceuticals (3 802), biotechnology (2 751).

Salipro Biotech Obtains Grant for Key Patent from the European Patent Office

Retrieved on: 
Thursday, March 14, 2024
Eurosport 1, Drug discovery, Business, EPO, G protein-coupled receptor, IP, European Patent Convention, Patent, Therapy, Pharmaceutical industry

STOCKHOLM, March 14, 2024 /PRNewswire/ -- Swedish biotech company Salipro Biotech AB, a pioneering biotech company focusing on challenging drug targets for the discovery of next-generation therapeutics, today announced that the European Patent Office (EPO) has granted a further patent in Salipro Biotech's growing patent portfolio: European Patent EP 3 955 895 B1, entitled 'Production of Salipro® particles'. This patent covers processes related to the Salipro® platform and represents a pivotal milestone that strengthens Salipro Biotech's position as a key drug discovery platform holder for difficult drug targets such as GPCRs, ion channels and transporters.

Key Points: 
  • This additional European patent will further strengthen Salipro Biotech's integrated IP portfolio protecting its proprietary Salipro® platform technology to stabilize challenging drug targets and enable the discovery and development of next-generation therapeutics.
  • STOCKHOLM, March 14, 2024 /PRNewswire/ -- Swedish biotech company Salipro Biotech AB, a pioneering biotech company focusing on challenging drug targets for the discovery of next-generation therapeutics, today announced that the European Patent Office (EPO) has granted a further patent in Salipro Biotech's growing patent portfolio: European Patent EP 3 955 895 B1, entitled 'Production of Salipro® particles'.
  • This patent is based on one of multiple patent filings of Salipro Biotech since 2016.
  • The grant of the European patent will provide Salipro Biotech's unique platform technology with a broader protection, further strengthening its patent portfolio to address unmet medical needs and accelerate drug discovery programs against undruggable targets.

Salipro Biotech Obtains Grant for Key Patent from the European Patent Office

Retrieved on: 
Thursday, March 14, 2024
Eurosport 1, Drug discovery, Business, EPO, G protein-coupled receptor, IP, European Patent Convention, Patent, Therapy, Pharmaceutical industry

STOCKHOLM, March 14, 2024 /PRNewswire/ -- Swedish biotech company Salipro Biotech AB, a pioneering biotech company focusing on challenging drug targets for the discovery of next-generation therapeutics, today announced that the European Patent Office (EPO) has granted a further patent in Salipro Biotech's growing patent portfolio: European Patent EP 3 955 895 B1, entitled 'Production of Salipro® particles'. This patent covers processes related to the Salipro® platform and represents a pivotal milestone that strengthens Salipro Biotech's position as a key drug discovery platform holder for difficult drug targets such as GPCRs, ion channels and transporters.

Key Points: 
  • This additional European patent will further strengthen Salipro Biotech's integrated IP portfolio protecting its proprietary Salipro® platform technology to stabilize challenging drug targets and enable the discovery and development of next-generation therapeutics.
  • STOCKHOLM, March 14, 2024 /PRNewswire/ -- Swedish biotech company Salipro Biotech AB, a pioneering biotech company focusing on challenging drug targets for the discovery of next-generation therapeutics, today announced that the European Patent Office (EPO) has granted a further patent in Salipro Biotech's growing patent portfolio: European Patent EP 3 955 895 B1, entitled 'Production of Salipro® particles'.
  • This patent is based on one of multiple patent filings of Salipro Biotech since 2016.
  • The grant of the European patent will provide Salipro Biotech's unique platform technology with a broader protection, further strengthening its patent portfolio to address unmet medical needs and accelerate drug discovery programs against undruggable targets.

GH Research Reports Full Year 2023 Financial Results and Provides Business Updates

Retrieved on: 
Thursday, February 29, 2024
PD, Research, New Drug Application, TRD, GHRS, FDA, BDII, Food, EPO, Rat, Psychiatry, Patent, PPD, Patient, IDR, DSM-IV codes, Clinical trial, Insurance, Psychotherapy, G&A, MDD, IND, European Patent Convention, Pharmaceutical industry

DUBLIN, Ireland, Feb. 29, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the year ended December 31, 2023, and provided updates on its business.

Key Points: 
  • DUBLIN, Ireland, Feb. 29, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the year ended December 31, 2023, and provided updates on its business.
  • As announced in November 2023, both trials were recruiting slower than anticipated, in part due to the closure, for business reasons, of one of the two sites activated in each trial.
  • Subsequently, we have implemented measures to strengthen recruitment of both trials, including the addition of further clinical trial sites.
  • For the trial in patients with PPD (GH001-PPD-203), we now expect completion and availability of top-line data in the third quarter of 2024.